Que Thanh Thanh Nguyen

Ms. Que Thanh Thanh Nguyen

Chung Ang University, Seoul, South Korea
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2020 in Anticancer Research
Verified
Journal Article
Open access
PDF file
ELEun-Ju Lee
Eun-Ju Lee
QNQue Thanh Thanh Nguyen
Que Thanh Thanh Nguyen
MLMooyul Lee
Mooyul Lee
Dickkopf-3 (DKK3), also known as REIC, is a secreted glycoprotein. DKK3 is aberrantly expressed in various types of human malignant tumours. Promoter methylation status, intracellular protein expression, and protein expression in tumour vessels are significantly correlated with clinical prognostic factors, including survival. In malignant cells, DKK3 is involved in the induction of apoptosis, inhibition of invasion, and remodelling of tumour vasculature. These activities are carried out via the regulation of the beta-catenin signalling and c-Jun N-terminal kinase-dependent cellular pathway, both of which are critical for carcinogenesis. This review explores the potential value of DKK3 as a clinical biomarker and a therapeutic candidate in human malignancies.

12 January 2023 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QNQue Thanh Thanh Nguyen
Que Thanh Thanh Nguyen
HRHyemin Rhee
Hyemin Rhee
MKMi Kyung Kim
Mi Kyung Kim
MLMoo Yeol Lee
Moo Yeol Lee
ELEun-Ju Lee
Eun-Ju Lee
Intra‐abdominal adhesion is a complication following abdominal surgery caused by the suppression of fibrinolytic activity and aggravated fibroblast invasion of the injured area, which may lead to chronic illnesses such as chronic pain, intestinal obstruction, and female infertility. This study hypothesized that lumbrokinase, a fibrinolytic enzyme extracted from the earthworm, supports the wound healing process. Therefore, we assessed the effect of lumbrokinase on intra‐abdominal adhesion. Lumbrokinase treatment significantly decreased the severity and the area of intra‐abdominal adhesion in vivo in a dose‐dependent manner compared with the controls (untreated and hyaluronate‐treated). Lumbrokinase‐associated adverse effects were not observed. Immunohistochemical analysis of adhesion tissues revealed a loosened adhesive band between tissues, coupled with significantly decreased peritoneal thickening in the lumbrokinase‐treated group versus the control group. Three‐dimensional spheroid, MTT, and scratch wound migration assays using the IMR‐90 human fibroblast cell line demonstrated that lumbrokinase significantly attenuated the migration and adhesive activity of fibroblasts without compromising cell proliferation. The luciferase assay and western blot analysis showed that lumbrokinase inhibited the AP‐1/ICAM‐1 cell adhesion signaling pathway. Therefore, lumbrokinase decreases intra‐abdominal adhesion and peritoneal thickening by augmenting fibrinolytic action and inhibiting fibroblast migration and adhesive activity via attenuation of the AP‐1/ICAM‐1 signaling pathway. Lumbrokinase is thus a promising agent to prevent intra‐abdominal adhesion.

12 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
QNQue Thanh Thanh Nguyen
Que Thanh Thanh Nguyen
PHPark Hwangshin
Park Hwangshin
TLTae Jin Lee
Tae Jin Lee
KCKyung-Mi Choi
Kyung-Mi Choi
Joong Yull ParkJoong Yull Park
Joong Yull Park
ELEun-Ju Lee
Eun-Ju Lee
Dickkopf-3 (DKK3), a tumor suppressor, is frequently downregulated in various cancers. However, the role of DKK3 in ovarian cancer has not been evaluated. This study aimed to assess aberrant DKK3 expression and its role in epithelial ovarian carcinoma. DKK3 expression was assessed using immunohistochemistry with tissue blocks from 82 patients with invasive carcinoma, and 15 normal, 19 benign, and 10 borderline tumors as controls. Survival data were analyzed using Kaplan–Meier and Cox regression analysis. Paclitaxel-resistant cells were established using TOV-21G and OV-90 cell lines. Protein expression was assessed using Western blotting and immunofluorescence analysis. Cell viability was assessed using the MT assay and 3D-spheroid assay. Cell migration was determined using a migration assay. DKK3 was significantly downregulated in invasive carcinoma compared to that in normal, benign, and borderline tumors. DKK3 loss occurred in 56.1% invasive carcinomas and was significantly associated with disease-free survival and chemoresistance in serous adenocarcinoma. DKK3 was lost in paclitaxel-resistant cells, while β-catenin and P-glycoprotein were upregulated. Exogenous secreted DKK3, incorporated by cells, enhanced anti-tumoral effect and paclitaxel susceptibility in paclitaxel-resistant cells, and reduced the levels of active β-catenin and its downstream P-glycoprotein, suggesting that DKK3 can be used as a therapeutic for targeting paclitaxel-resistant cancer.

1 January 2021 in BioMed Research International
Verified
Journal Article
Open access
PDF file
QNQue Thanh Thanh Nguyen
Que Thanh Thanh Nguyen
THThi Xoan Hoang
Thi Xoan Hoang
HRHyunjin Ryu
Hyunjin Ryu
KOKook-Hwan Oh
Kook-Hwan Oh
JKJae Young Kim
Jae Young Kim
Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by uncontrollable epithelial cell growth, cyst formation, and kidney malfunction. In the present study, we investigated the antiproliferative effects of the treatment with the combination of paclitaxel (PAC) and all‐trans retinoic acid (ATRA) on ADPKD epithelial cells. Our results show that the combined treatment with 1 nM PAC and 10 nM ATRA significantly suppressed ADPKD cell proliferation (20%), while the treatment with ATRA or PAC alone had no such effect. Treatment with PAC and ATRA induced cell cycle arrest at the G2/M phase and apoptosis by upregulating p53 and caspase‐8 expression and increased the intracellular calcium (Ca2+) level possibly by enhancing Ca2+ uptake via plasma membrane channels. In addition, this treatment suppressed extracellular signal‐regulated kinase signaling possibly through mitogen‐activated protein kinase phosphatase‐1 activation. Thus, the combination of PAC and ATRA can be explored as a potential treatment regimen for ADPKD.

1 February 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ELEun-Ju Lee
Eun-Ju Lee
MCMinji Cho
Minji Cho
SRSeung Bae Rho
Seung Bae Rho
Junsoo ParkJunsoo Park
Junsoo Park
DCDhan-Ah Chae
Dhan-Ah Chae
QNQue Thanh Thanh Nguyen
Que Thanh Thanh Nguyen